Humanized IgG1 monoclonal antibody against GD2, Leukine
201
Phase 2 small_molecule active
Quick answer
Humanized IgG1 monoclonal antibody against GD2, Leukine for Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow is a Phase 2 program (small_molecule) at Y-Mabs Therapeutics A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Y-Mabs Therapeutics A/S
- Indication
- Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active